Brookline Capital (BCAC) Shareholders Approve Apexigen Deal
by Marlena Haddad on 2022-07-28 at 7:19am

Brookline Capital (NASDAQ:BCAC) announced in an 8-K this morning that its shareholders approved its combination with Apexigen at a special meeting July 27.

The filing did not include redemption figures, but the transaction also did not have a minimum cash condition beyond listing requirements. Brookline brought a $15 million PIPE alongside its trust in the deal and Lincoln Park also agreed to purchase up to $50 million of the combined entity’s stock in the two years following the transaction’s close.

Brookline traded below its estimated pro rata trust value of $10.22 throughout its July 25 redemption deadline, but has since soared to a close Wednesday at $10.75. Following the deal’s close, Apexigen is expected to trade on the Nasdaq under the symbol “APGN”.

The parties initially announced the $278 million combination on March 18. San Carlos, California-based Apexigen is developing a range of immunological cancer treatments with four currently in Phase II trials.

It announced the results of its Phase II trials to treat pancreatic cancer with its sotigalimab drug candidate in June.


ADVISORS

  • Brookline Capital Markets is acting as capital markets advisor to Brookline Capital Acquisition Corp.
  • Wedbush PacGrow is acting as exclusive strategic financial advisor to Apexigen.
  • DLA Piper LLP (US) is serving as legal advisor to Brookline Capital Acquisition Corp.
  • Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal advisor to Apexigen.
Brookline Capital (BCAC) Shareholders Approve Apexigen Deal
Recent Posts
by Nicholas Alan Clayton on 2025-07-11 at 8:24am

At the SPAC of Dawn Lately de-SPACs have been announcing corporate moves of a kind frequently in trios as was the case earlier this week when WeBull (NASDAQ:BULL), AST SpaceMobile (NASDAQ:ASTS) and Quantum-Si (NASDAQ:QSI) all announced major equity raises. This week, it is a trio of de-SPACs making reverse stock splits in unison, which is...

by Kristi Marvin on 2025-07-10 at 8:31am

A look at Plus’ software-first approach to autonomous trucking. After years of investment and excitement, the dawn of self-driving cars and trucks is now here. The question now is which business model among autonomous driving technology companies will win out? This week, we speak with David Liu, CEO of autonomous trucking company Plus. Plus announced...

by Nicholas Alan Clayton on 2025-07-10 at 8:27am

At the SPAC of Dawn One thing that SPAC investors can typically count on while their money is invested in a SPAC’s trust is that it is going to grow one way or the other between now and their next redemption opportunity, but the devil can occasionally be in the details. In 2024, it became...

by Nicholas Alan Clayton on 2025-07-09 at 12:57pm

Thunderstone has filed for a $50 million SPAC to put a new first-time Asia-based team in action on a generalist hunt. The new SPAC is offering investors a right to a 1/8 share in each unit with 18 months to initially complete a business combination. It is the 8th fresh S-1 filed with underwriter D....

by Nicholas Alan Clayton on 2025-07-09 at 8:22am

At the SPAC of Dawn In a trading session that may find itself built around the release of Fed minutes at 2 pm ET this afternoon, a pair of SPAC targets have added their own fresh information to the mix. Enterprise AI firm Fusemachines, which has a pending combination with CSLM (OTC:CSLMF), put out a...

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved